分析接受新辅助化疗 (NAC) 后进行经口腔机器人手术 (TORS) 的 III-IV 期喉咽癌患者的肿瘤学和功能结局。这是一项单中心的回顾性队列研究，共纳入 100 名 III-IV 期个体喉或咽癌患者（中位年龄为 67.0 岁）。所有患者均接受 NAC 后进行 TORS 和风险校正的辅助治疗。主要结局是无复发生存率 (RFS)。中位随访时间为 24.0 个月。2 年估计的 (95% CI) 总生存率、疾病特异生存率和 RFS 分别为 75％（66％-85％）、84％（76％-92％）和 65％（56％-76％）。在 11 名复发在原发部位的患者中，有 3 名接受了挽救性全喉切除术，3 名接受了挽救性 CRT，其余患者接受了缓解或支持性治疗。手术后 6 个月，有 17 名患者仍然需要气管切开或气孔固定器，而有 15 名依赖胃造瘘。Cox 多变量分析表明，临床分期、NAC 循环次数和 LVI 的存在与 RFS 存在独立相关性。本研究表明，NAC 后进行 TORS 可以在 III-IV 期喉咽癌患者中获得良好的肿瘤控制、生存和器官保留率。版权所有©2023 Elsevier Ltd. 发表。

To analyze the oncological and functional outcomes of patients with stage III-IV laryngo-hypopharyngeal cancer who underwent neoadjuvant chemotherapy (NAC) with subsequent transoral robotic surgery (TORS).A single-center retrospective cohort study included a total of 100 patients (median age of 67.0) affected by stage III-IV supraglottic or hypopharyngeal cancer. All patients underwent NAC followed by TORS and risk-adjusted adjuvant therapy. The primary outcome was recurrence-free survival (RFS).The median follow-up time was 24.0 months. Estimated 2-year (95% CI) OS, DSS, and RFS were 75% (66% - 85%), 84% (76% - 92%), and 65% (56% - 76%), respectively. Among the 11 patients who relapsed on the primary site, 3 underwent salvage total laryngectomy, 3 underwent salvage CRT, and the others receive palliation or supportive care. At 6 months from surgery, 17 patients were still tracheostomized or had a stoma retainer, while 15 were gastrostomy dependent. At the Cox multivariable analysis, the clinical stage at presentation, the number of NAC cycles, and the presence of LVI were found to be independently correlated with the RFS.This study demonstrates that NAC followed by TORS can obtain good tumor control, survival, and organ preservation rates in stage III-IV laryngo-hypopharyngeal cancer.Copyright © 2023. Published by Elsevier Ltd.